Kim Yunhwa, Hwang Ji-Young, Lee Kyung-Min, Lee Eunsil, Park Hosun
Department of Microbiology, College of Medicine, Yeungnam University, Daegu 42415, Korea.
Department of Pediatrics, College of Medicine, Yeungnam University, Daegu 42415, Korea.
Vaccines (Basel). 2021 May 12;9(5):492. doi: 10.3390/vaccines9050492.
The prevalence of varicella is especially high among children in the age group of 4-6 years in South Korea, regardless of vaccination. We investigated the immune status of healthy children enrolled in day-care centers and compared pre- and post-vaccination immunity. Antibody titers were measured using a glycoprotein enzyme-linked immunosorbent assay (gpEIA) kit, and the seroconversion rate was assessed using a fluorescent antibody to membrane antigen (FAMA) test. Among 541 vaccinated children, 109 (20.1%) had breakthrough varicella. However, 13 (72.2%) of the 18 unvaccinated children had a history of varicella. The gpEIA geometric mean titers (GMTs) of pre- and 5 weeks post-vaccination in 1-year-old children were 14.7 and 72 mIU/mL, respectively, and the FAMA seroconversion rate was 91.1%. The gpEIA GMTs of 2-, 3-, 4-, 5-, and 6-year-old children were 104.1, 133.8, 223.5, 364.1, and 353.0 mIU/mL, respectively. Even though the gpEIA GMT increased with age, the pattern of gpEIA titer distribution in 4- to 6-year-old vaccinees without varicella history represented both waning immunity and natural boosting immunity. These results suggest that some vaccinees are vulnerable to varicella infection. Therefore, it is necessary to consider a two-dose varicella vaccine regimen in South Korea.
在韩国,无论是否接种疫苗,水痘在4至6岁的儿童中患病率尤其高。我们调查了日托中心健康儿童的免疫状况,并比较了接种疫苗前后的免疫力。使用糖蛋白酶联免疫吸附测定(gpEIA)试剂盒测量抗体滴度,并使用膜抗原荧光抗体(FAMA)试验评估血清转化率。在541名接种疫苗的儿童中,109名(20.1%)发生了突破性水痘。然而,18名未接种疫苗的儿童中有13名(72.2%)有水痘病史。1岁儿童接种疫苗前和接种后5周的gpEIA几何平均滴度(GMTs)分别为14.7和72 mIU/mL,FAMA血清转化率为91.1%。2岁、3岁、4岁、5岁和6岁儿童的gpEIA GMTs分别为104.1、133.8、223.5、364.1和353.0 mIU/mL。尽管gpEIA GMT随年龄增加,但在没有水痘病史的4至6岁接种疫苗者中,gpEIA滴度分布模式既代表了免疫力下降,也代表了自然增强免疫力。这些结果表明,一些接种疫苗者易患水痘感染。因此,在韩国有必要考虑采用两剂水痘疫苗接种方案。